标题
Tyrosine Kinase Inhibitors in Osteosarcoma: Adapting Treatment Strategies
作者
关键词
-
出版物
Journal of Bone Oncology
Volume -, Issue -, Pages 100511
出版商
Elsevier BV
发表日期
2023-11-03
DOI
10.1016/j.jbo.2023.100511
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Retrospective review of safety and efficacy of anlotinib in advanced osteosarcoma with metastases after failure of standard multimodal therapy
- (2023) Hanqing Li et al. Asia-Pacific Journal of Clinical Oncology
- Safety and efficacy of multiple tyrosine kinase inhibitors in pediatric/adolescent and young adult patients with relapsed or refractory osteosarcomas: A single‐institution retrospective analysis
- (2023) Masanaka Sugiyama et al. PEDIATRIC BLOOD & CANCER
- Recent advances on anti-angiogenic multi-receptor tyrosine kinase inhibitors in osteosarcoma and Ewing sarcoma
- (2023) Emmy D. G. Fleuren et al. Frontiers in Oncology
- Pazopanib in Patients with Osteosarcoma Metastatic to the Lung: Phase 2 Study Results and the Lessons for Tumor Measurement
- (2022) Paul Frankel et al. Journal of Oncology
- RET receptor signaling: Function in development, metabolic disease, and cancer
- (2022) Masahide TAKAHASHI PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
- Correlation of nuclear pIGF-1R/IGF-1R and YAP/TAZ in a tissue microarray with outcomes in osteosarcoma patients
- (2022) Eric R. Molina et al. Oncotarget
- Bevacizumab, With Sorafenib and Cyclophosphamide Provides Clinical Benefit for Recurrent or Refractory Osseous Sarcomas in Children and Young Adults
- (2022) Jessica Bodea et al. Frontiers in Oncology
- Integrated DNA Copy Number and Expression Profiling Identifies IGF1R as a Prognostic Biomarker in Pediatric Osteosarcoma
- (2022) Aaron M. Taylor et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- The Combination of Anlotinib and Gemcitabine/Docetaxel in Patients with Metastatic Osteosarcoma Who Have Failed Standard Chemotherapy
- (2022) Tian Wang et al. Cancer Management and Research
- Efficacy and safety of apatinib in the treatment of osteosarcoma: a single-arm meta-analysis among Chinese patients
- (2021) Hui Yao et al. BMC CANCER
- Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma
- (2021) Marissa A. Just et al. PEDIATRIC BLOOD & CANCER
- Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas
- (2021) Brian Schulte et al. BRITISH JOURNAL OF CANCER
- OLIE, ITCC-082: a Phase II trial of lenvatinib plus ifosfamide and etoposide in relapsed/refractory osteosarcoma
- (2021) Nathalie Gaspar et al. Future Oncology
- Efficacy and safety of TAS-115, a novel oral multi-kinase inhibitor, in osteosarcoma: an expansion cohort of a phase I study
- (2021) Akira Kawai et al. INVESTIGATIONAL NEW DRUGS
- Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study
- (2021) Nathalie Gaspar et al. LANCET ONCOLOGY
- Apatinib plus ifosfamide and etoposide for relapsed or refractory osteosarcoma: A retrospective study in two centres
- (2021) Lu Xie et al. Oncology Letters
- Efficacy and safety of anlotinib in patients with unresectable or metastatic bone sarcoma: A retrospective multiple institution study
- (2021) Zhiyong Liu et al. Cancer Medicine
- Phase I/II study of single-agent lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma (ITCC-050)☆
- (2021) N. Gaspar et al. ESMO Open
- Retrospective review of the activity and safety of apatinib and anlotinib in patients with advanced osteosarcoma and soft tissue sarcoma
- (2020) Zhichao Tian et al. INVESTIGATIONAL NEW DRUGS
- Cabozantinib in patients with advanced Ewing sarcoma or osteosarcoma (CABONE): a multicentre, single-arm, phase 2 trial
- (2020) Antoine Italiano et al. LANCET ONCOLOGY
- Anorexia, Hypertension, Pneumothorax, and Hypothyroidism: Potential Signs of Improved Clinical Outcome Following Apatinib in Advanced Osteosarcoma
- (2020) Lu Xie et al. Cancer Management and Research
- The efficacy and safety of Apatinib mesylate in the treatment of metastatic osteosarcoma patients who progressed after standard therapy and the VEGFR2 gene polymorphism analysis
- (2020) Jia-Yong Liu et al. International Journal of Clinical Oncology
- Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial
- (2020) Lu Xie et al. Journal for ImmunoTherapy of Cancer
- Secondary Osteosarcoma After Bone Marrow Transplant: An Aggressive Disease
- (2020) Marta Pierobon et al. Journal of Adolescent and Young Adult Oncology
- Prognostic role of the recepteur d'origine nantais (RON) expression in primary high-grade osteosarcoma
- (2020) Sheng-Lin Wang et al. JOURNAL OF ORTHOPAEDIC SCIENCE
- Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target?
- (2020) Zhichao Tian et al. Frontiers in Oncology
- Regorafenib-Associated Acute Pancreatitis Diagnosed on 18F-FDG PET/CT
- (2020) Melvika Pereira et al. CLINICAL NUCLEAR MEDICINE
- Cardiovascular toxicity of regorafenib for heavily‐treated osteosarcoma
- (2020) Yuya Saito et al. PEDIATRICS INTERNATIONAL
- Overactivation of the IGF signalling pathway in osteosarcoma: a potential therapeutic target?
- (2020) Baptiste Ameline et al. Journal of Pathology Clinical Research
- Integration of genomic copy number variations and chemotherapy-response biomarkers in pediatric sarcoma
- (2019) Lijun Cheng et al. BMC Medical Genomics
- Hypoxia promotes osteosarcoma cell proliferation and migration through enhancing platelet-derived growth factor-BB/platelet-derived growth factor receptor-β axis
- (2019) Dan Zhang et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy
- (2019) Zhichao Tian et al. MEDICINE
- Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma
- (2019) Lara E. Davis et al. JOURNAL OF CLINICAL ONCOLOGY
- The Pan‐Cancer Landscape of Coamplification of the Tyrosine Kinases KIT, KDR, and PDGFRA
- (2019) Umut Disel et al. ONCOLOGIST
- Pazopanib in the Treatment of Bone Sarcomas: Clinical Experience
- (2019) Ninna Aggerholm-Pedersen et al. Translational Oncology
- Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China
- (2018) Lu Xie et al. BMC CANCER
- Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1
- (2018) Binyan Lin et al. GENE
- Pazopanib in relapsed osteosarcoma patients: report on 15 cases
- (2018) Alessandra Longhi et al. ACTA ONCOLOGICA
- Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
- (2018) Guoshuang Shen et al. Journal of Hematology & Oncology
- Sorafenib in patients with progressed and refractory bone tumors
- (2018) Anna Raciborska et al. MEDICAL ONCOLOGY
- Efficacy and safety of apatinib in advance osteosarcoma with pulmonary metastases
- (2018) Kai Zheng et al. MEDICINE
- A study of axitinib, a VEGF receptor tyrosine kinase inhibitor, in children and adolescents with recurrent or refractory solid tumors: A Children’s Oncology Group phase 1 and pilot consortium trial (ADVL1315)
- (2018) James I. Geller et al. CANCER
- Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study
- (2018) Florence Duffaud et al. LANCET ONCOLOGY
- Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial
- (2018) Lu Xie et al. ONCOLOGIST
- Pazopanib for second recurrence of osteosarcoma in pediatric patients
- (2017) Katsutsugu Umeda et al. PEDIATRICS INTERNATIONAL
- Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma
- (2017) Sam Behjati et al. Nature Communications
- Molecular Imaging of IGF-1R in Cancer
- (2017) Yingying Sun et al. Molecular Imaging
- Evaluation of the Expression and Role of IGF Pathway Biomarkers in Human Sarcomas
- (2017) F. Lin et al. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY
- Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
- (2016) Neyssa M Marina et al. LANCET ONCOLOGY
- High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells
- (2016) Hidenori Fujita et al. PLoS One
- Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC’S (Observatoire de l’Utilisation des Thérapies Ciblées dans les Sarcomes)
- (2015) Mathilde Penel-Page et al. BMC CANCER
- SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma
- (2015) Scott M. Schuetze et al. CANCER
- Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
- (2015) Giovanni Grignani et al. LANCET ONCOLOGY
- Regulation of osteosarcoma cell lung metastasis by the c-Fos/AP-1 target FGFR1
- (2015) D Weekes et al. ONCOGENE
- Pazopanib in metastatic osteosarcoma: Significant clinical response in three consecutive patients
- (2014) Akmal Safwat et al. ACTA ONCOLOGICA
- Physiological Functions and Underlying Mechanisms of Fibroblast Growth Factor (FGF) Family Members: Recent Findings and Implications for Their Pharmacological Application
- (2014) Toru Imamura BIOLOGICAL & PHARMACEUTICAL BULLETIN
- Fibroblastic growth factor receptor 1 amplification in osteosarcoma is associated with poor response to neo-adjuvant chemotherapy
- (2014) M. Fernanda Amary et al. Cancer Medicine
- Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients
- (2013) Ju Han et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- The C-Kit Receptor-Mediated Signal Transduction and Tumor-Related Diseases
- (2013) Jing Liang et al. International Journal of Biological Sciences
- Expression of c-kit Protein and Mutational Status of the c-kit Gene in Osteosarcoma and Their Clinicopathological Significance
- (2013) H Wei et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- Prognostic significance of VEGF expression in osteosarcoma: a meta-analysis
- (2013) Xiao-Wei Yu et al. TUMOR BIOLOGY
- The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer
- (2013) C Hage et al. Cell Death & Disease
- The important roles of RET, VEGFR2 and the RAF/MEK/ERK pathway in cancer treatment with sorafenib
- (2012) Wei-feng Mao et al. ACTA PHARMACOLOGICA SINICA
- Neoadjuvant Chemotherapy With Methotrexate, Cisplatin, and Doxorubicin With or Without Ifosfamide in Nonmetastatic Osteosarcoma of the Extremity: An Italian Sarcoma Group Trial ISG/OS-1
- (2012) Stefano Ferrari et al. JOURNAL OF CLINICAL ONCOLOGY
- Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines
- (2012) A N Rettew et al. Oncogenesis
- A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
- (2011) G. Grignani et al. ANNALS OF ONCOLOGY
- Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, includingVEGFA, in human osteosarcoma
- (2011) Jilong Yang et al. CANCER
- YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo
- (2011) Shu Tian et al. CANCER SCIENCE
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Increased expression of insulin-like growth factor-1 receptor is correlated with tumor metastasis and prognosis in patients with osteosarcoma
- (2011) Yin-He Wang et al. JOURNAL OF SURGICAL ONCOLOGY
- Pazopanib: Clinical development of a potent anti-angiogenic drug
- (2010) Fabio A.B. Schutz et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours
- (2010) Hester van Cruijsen et al. EUROPEAN JOURNAL OF CANCER
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors
- (2010) Elizabeth Fox et al. JOURNAL OF CLINICAL ONCOLOGY
- Expression of platelet-derived growth factor-alpha receptor in human osteosarcoma is not a predictor of outcome
- (2010) Irene Sulzbacher et al. PATHOLOGY
- Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma
- (2009) Ayesha Abdeen et al. CANCER
- Ret-Dependent Cell Rearrangements in the Wolffian Duct Epithelium Initiate Ureteric Bud Morphogenesis
- (2009) Xuan Chi et al. DEVELOPMENTAL CELL
- Phase II Multicenter Trial of Imatinib in 10 Histologic Subtypes of Sarcoma Using a Bayesian Hierarchical Statistical Model
- (2009) Rashmi Chugh et al. JOURNAL OF CLINICAL ONCOLOGY
- Validation of PDGFR and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib
- (2008) A. M. L. Coluccia et al. BLOOD
- Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma
- (2008) Tadahiko Kubo et al. CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started